Darnax Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
- Paid Up Capital ₹ 2.10 M
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -25.54%
- Profit Growth -66.48%
- Ebitda -56.29%
- Net Worth 11.73%
- Total Assets 31.00%
About Darnax Pharma
Darnax Pharma Private Limited (DPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 09 August 2011 and has a history of 13 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dariyadevi Hiran, Naresh Hiran, and Rekha Hiran serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH2011PTC220735
- Company No.
220735
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Aug 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Darnax Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Hiran  | Additional Director | 07-Feb-2023 | Current |
| Dariyadevi Hiran | Director | 09-Aug-2011 | Current |
| Rekha Hiran | Director | 01-Mar-2018 | Current |
Financial Performance of Darnax Pharma.
Darnax Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 25.54% decrease. The company also saw a substantial fall in profitability, with a 66.48% decrease in profit. The company's net worth Soared by an impressive increase of 11.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Darnax Pharma?
Unlock access to Darnax Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Actgen Pharma Private LimitedDariyadevi Hiran is a mutual person
Sunflower Trading And Investment Pvt LtdDariyadevi Hiran is a mutual person
- Dnr Pharma Llp
Naresh Hiran and Rekha Hiran are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Darnax Pharma?
Unlock and access historical data on people associated with Darnax Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Darnax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Darnax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.